Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 14pembrolizumab 8Radiotherapy 7Nivolumab 7Radiotherapy, Intensity-Modulated 5Cetuximab 5Carboplatin 5Fluorouracil 4durvalumab 3Radiosurgery 3Magnetic Resonance Spectroscopy 3Docetaxel 3fluoromisonidazole 2epacadostat 2Standard of Care 2Specimen Handling 2Photochemotherapy 2Paclitaxel 2Drug Therapy 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Capecitabine 2C188-9 compound 2zimberelimab 1yeast-CEA vaccine 1vandetanib 1temoporfin 1talazoparib 1ruxolitinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Squamous Cell Carcinoma of Head and Neck × yeast-CEA vaccine × Clear all
NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡